CPI report health care inflation

Inflation for health care encourages higher coverage costs, stage setup for what could be the greatest increase in health care by large employers in 15 years.

Medical care costs increased by 4.2% on an annual basis, in accordance with the consumer rate index, compared to the total inflation rate of 2.9%. The costs of the doctor’s visit increased by 3.5%, while hospitals and outpatient services jumped 5.3%.

These price increases contribute to greater health insurance costs by 2026. Years. Consumers who do not qualify for state subsidies for the purchase of health councils may face double digres of Premium increases for next year, in accordance with the early insurer files.

Workers with employers’ health coverage could also pay higher premium and out of pocket costs next year.

Large employers project their total health coverage costs will increase on average 9% in 2026. years, according to several surveys about the business group, which would be the highest level of health inflation since 2010. years.

More than half of the companies surveyed benefits of a consulting company Meter Earlier this year, he said to think about the transfer of some of those increased workers, but the business group on health says that most employers are in it research They are looking for other ways to reduce costs.

“Employers were bleak in every way, from transferring employees. This year, they could seem to be employed, but again,” Ellen Kelsai said, “Ellen Kelsai said,” Ellen Kelsai said.

Companies that review BGGH projecting 12% increase in pharmaceutical costs next year, at the top of 11% visit to drugs against cancer and diabetes and gojazbista treatments NEW NORDISK’S Vegs and Eli Lilli’s Zepbound.

“Cancers in the fourth year in a row, a top condition of health – cancer at younger centuries, later diagnoses,” Kelsai said, who added that the principles of drugs for weight loss are close.

“When it comes to obesity treatment, it was a space that mostly made the most of them and was what it encouraged a lot of this pharmaceutical spending,” she said.

Almost two thirds of employers with 20,000 workers or more offers access to weight loss drugs known as GLP-1S, according to Mercer. Less than half of the small employers of the respondent plans to offer access in 2026. Years.

With growing demand for drugs, more companies are tightening the conditions for suitability and starting to explore more accessible ways to provide access to their employees, including the money payment market.

Health account information show that more workers are converted into a direct consumer, including Eli Lilli’s Lilli Direct and the new Nordisk’s Novokare Internet pharmacies, which both offer their weight loss drugs at about half the price of the list greater than $ 1,000.

GLP-1 purchases are now a top category of cash consumption in the revisional flexible account of consumption and health savings, for costs not covered by insurance, in accordance with the Director General of Health Payment.

“We see spending since last year, this was used like Lilly Direct, like Ro, like him and her, and it’s a growing segment,” he said the founder of the Brian Whorley founder.

But employers take care that cash payment trend leaves lower income workers from the equation, because they cannot afford the costs outside their pockets. This encourages discussions about how their companies can get cash payments to help improve the more effective access to employees.

Only-insured employers directly contracted with the so-called excellence centers for special medical care such as cancer treatment and common replacement. But I can’t do the same for many drugs right now. According to the agreements with pharmacies management companies, or PBMs, as drugs and employers would violate their contracts using a direct process of paying money.

But employers are increasingly pressing PBMS for better options, says BGH Kelsai. They start considering new types of managers, who propose new models of drug payment in development pipeline.

“There are some new entities – some starts in this area – which build products and solutions where they go on behalf of a collected group of employers to negotiate with manufacturers on certain cellular and gene therapies,” she said.

Whorley with calling call Challenge to GLP-1 more accessible for employers and PBMS stress.

“They are in a perfect type of Venn diagram of clinically effective drugs that change people’s lives, that will more force the choice,” when it comes to funding, Vhorley said. “If we get that right, it can provide a draft for all drugs like GLP-1S that will … represent challenges for health plans.”